Agile Therapeutics Inc. (NASDAQ:AGRX)’s share price fell 3.7% on Tuesday . The company traded as low as $7.18 and last traded at $7.27, with a volume of 135,869 shares traded. The stock had previously closed at $7.55.

A number of research firms have weighed in on AGRX. Noble Financial reiterated a “buy” rating and issued a $15.00 price target on shares of Agile Therapeutics in a research report on Friday, July 8th. FBR & Co reiterated a “buy” rating on shares of Agile Therapeutics in a research report on Friday, June 17th. Cantor Fitzgerald reiterated a “buy” rating on shares of Agile Therapeutics in a research report on Tuesday, May 31st. Finally, Zacks Investment Research lowered shares of Agile Therapeutics from a “buy” rating to a “hold” rating in a research report on Wednesday, May 11th. One research analyst has rated the stock with a hold rating and five have given a buy rating to the stock. The company presently has an average rating of “Buy” and a consensus price target of $15.00.

The firm has a 50-day moving average price of $7.59 and a 200 day moving average price of $6.77. The company’s market capitalization is $202.34 million.

Agile Therapeutics (NASDAQ:AGRX) last announced its quarterly earnings data on Monday, May 9th. The specialty pharmaceutical company reported ($0.27) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.38) by $0.11. Equities research analysts expect that Agile Therapeutics Inc. will post ($1.12) EPS for the current year.

An institutional investor recently raised its position in Agile Therapeutics stock. Marshall Wace LLP increased its stake in shares of Agile Therapeutics Inc. (NASDAQ:AGRX) by 4.9% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 129,769 shares of the specialty pharmaceutical company’s stock after buying an additional 6,099 shares during the period. Marshall Wace LLP owned 0.58% of Agile Therapeutics worth $1,267,000 at the end of the most recent quarter.

Agile Therapeutics, Inc is a women’s health specialty pharmaceutical company. The Company is focused in the development and commercialization of prescription contraceptive products. The Company has developed a transdermal patch technology, called Skinfusion. The Company’s lead product candidate is Twirla, also known as AG200-15, is a combined hormonal contraceptive (CHC) patch.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.